Caribou Biosciences (NASDAQ:CRBU) Issues Quarterly Earnings Results

Caribou Biosciences (NASDAQ:CRBU) announced its quarterly earnings data on Wednesday. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.08, FiscalAI reports. The business had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.28 million. Caribou Biosciences had a negative return on equity of 84.17% and a negative net margin of 1,189.14%.

Caribou Biosciences Price Performance

Shares of Caribou Biosciences stock opened at $1.61 on Friday. Caribou Biosciences has a 1 year low of $1.38 and a 1 year high of $3.54. The firm’s 50-day moving average is $1.69 and its 200 day moving average is $1.84. The stock has a market cap of $159.68 million, a price-to-earnings ratio of -1.13 and a beta of 2.38.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CRBU. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Friday, July 17th. HC Wainwright lifted their target price on shares of Caribou Biosciences from $9.00 to $11.00 and gave the company a “buy” rating in a report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.67.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CRBU. Creative Planning bought a new stake in shares of Caribou Biosciences during the second quarter valued at approximately $25,000. Hudson Bay Capital Management LP bought a new stake in shares of Caribou Biosciences in the 2nd quarter worth $30,000. Russell Investments Group Ltd. raised its stake in shares of Caribou Biosciences by 80.0% in the fourth quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock worth $39,000 after purchasing an additional 10,824 shares during the last quarter. Credit Agricole S A purchased a new position in shares of Caribou Biosciences in the third quarter worth $68,000. Finally, US Bancorp DE lifted its holdings in shares of Caribou Biosciences by 18,624.0% during the third quarter. US Bancorp DE now owns 34,265 shares of the company’s stock valued at $80,000 after purchasing an additional 34,082 shares in the last quarter. Institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.